Has Inavolisib been included in the National Medical Insurance List?

Inavolisib (Inavolisib), as a new type of PI3K inhibitor, is mainly used to treat breast cancer and other solid tumors driven by specific gene mutations. The drug has been approved for marketing in China, providing domestic patients with a new targeted treatment option. However, as of now, Inalise has not been included in the national medical insurance directory, so patients still need to purchase it at their own expense when using it in China, which imposes a relatively heavy financial burden.

The common specifications of inaliset include 3mg7tablets4plates and 9mg7tablets4plates, to meet the treatment needs of different patients. Since the drug has just been launched, the market supply is still in its early stages and the price is relatively high. It is expected that each box will sell for about 30,000 yuan in the domestic market. In comparison, the price in overseas markets is higher, with each box selling for more than 200,000 yuan. Price fluctuations are also affected by various factors such as exchange rates.

Currently, there is no generic version of Inarisep on the market in China, and all products sold on the market are original imported products or officially authorized products. This also results in its relatively stable and high price, and patients need to consider their affordability when choosing medications. Since it is not included in medical insurance, patients cannot enjoy the medical insurance reimbursement policy when purchasing. They mainly purchase through regular hospital pharmacies or authorized dealers.

Overall, as an innovative targeted drug, the domestic launch of inarisep has brought more treatment hope to patients, but it has not yet been included in the medical insurance catalog, which limits its popularity. In the future, with the accumulation of more clinical data and the advancement of medical insurance negotiations, inarisep is expected to be gradually included in the medical insurance system, reducing patients' financial pressure and improving accessibility. Patients should consult a professional doctor before taking medication and choose a reasonable treatment plan based on their condition and financial status.

Reference materials:https://www.drugs.com/